LARIMAR THERAPEUTICS, INC.: basic weighted-average shares
Basic weighted-average shares for LARIMAR THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All LARIMAR THERAPEUTICS, INC. financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2024-12-31. The SEC response was captured on 2026-09-19.
Reading these values
This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Context from the filing
Larimar Therapeutics' 2023 and 2024 statements display dollar losses in thousands but full share counts and unscaled EPS. Before their August 11, 2023 exercise, prefunded warrants were already included in basic weighted-average shares because little or no consideration was required; exercise issued 628,403 common shares. Options outstanding at year-end (4,888,502 in 2023 and 7,135,390 in 2024) are excluded as anti-dilutive during losses, not added to the reported denominator. Basic and diluted loss EPS are equal. Read the source filing.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-01-01 | 2024-12-31 | 61,256,084 | shares | 2025-03-24 | 10-K · 0000950170-25-043925 |
| 2023-01-01 | 2023-12-31 | 43,901,241 | shares | 2025-03-24 | 10-K · 0000950170-25-043925 |
| 2022-01-01 | 2022-12-31 | 25,761,394 | shares | 2024-03-14 | 10-K · 0000950170-24-031529 |
| 2021-01-01 | 2021-12-31 | 17,164,284 | shares | 2023-03-14 | 10-K · 0000950170-23-007855 |
| 2020-01-01 | 2020-12-31 | 11,883,155 | shares | 2022-03-25 | 10-K · 0000950170-22-004637 |
Related financial histories
- LARIMAR THERAPEUTICS, INC.: total assets
- LARIMAR THERAPEUTICS, INC.: total liabilities
- LARIMAR THERAPEUTICS, INC.: stockholders equity
- LARIMAR THERAPEUTICS, INC.: cash and cash equivalents
- LARIMAR THERAPEUTICS, INC.: net income or loss
- LARIMAR THERAPEUTICS, INC.: operating cash flow
- LARIMAR THERAPEUTICS, INC.: capital expenditure payments
- LARIMAR THERAPEUTICS, INC.: revenue
- LARIMAR THERAPEUTICS, INC.: financing cash flow
- LARIMAR THERAPEUTICS, INC.: investing cash flow
- LARIMAR THERAPEUTICS, INC.: retained earnings or deficit
- LARIMAR THERAPEUTICS, INC.: diluted weighted-average shares
- LARIMAR THERAPEUTICS, INC.: basic earnings per share
- LARIMAR THERAPEUTICS, INC.: diluted earnings per share
- LARIMAR THERAPEUTICS, INC.: net property, plant and equipment
- LARIMAR THERAPEUTICS, INC.: share-based compensation expense
- LARIMAR THERAPEUTICS, INC.: operating income or loss
- LARIMAR THERAPEUTICS, INC.: current assets
- LARIMAR THERAPEUTICS, INC.: interest expense
- LARIMAR THERAPEUTICS, INC.: current liabilities
- LARIMAR THERAPEUTICS, INC.: current accounts payable
- LARIMAR THERAPEUTICS, INC.: operating expenses
- LARIMAR THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- LARIMAR THERAPEUTICS, INC. / CIK 0001374690
- Captured
- 2026-09-19T11:17:50.717Z
- SEC response SHA-256
08638b3759f4b65e6e121b92d928b796b8584ccbcb8cfc63b68c5bc067fd2552
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001374690.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))